Earnings Call: Q3 2017

Nov 1, 2017

Welcome to Teladoc's 3rd Quarter 20 17 Earnings Conference Call and Webcast. At this time, all participants have been placed in a listen only mode and the floor will be open for your questions following management's prepared remarks. It is now my pleasure to turn the floor over to Adam Vander Voort, Chief Legal Officer. You may begin. Thank you, operator, and good afternoon to everyone. We look forward to discussing our Q3 2017 results with you today. Joining me for Teladoc's conference call are Jason Gorevic, our Chief Executive Officer and Mark Hirshhorn, our Chief Operating Officer and Chief Financial Officer. Today, after the market closed, we issued a press release announcing our Q3 2017 results and filed our quarterly report on Form 10 Q. The release and the report are available on the Investor Relations section of teladoc.com. As a reminder, Teladoc intends to avail itself of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain statements made during this call will be forward looking statements within the meaning of that law. These forward looking statements are subject to risks, uncertainties and other factors that could cause Teladoc's actual results to differ materially from those expressed or implied by the forward looking statements. For additional information on the risks facing Teladoc, please refer to our filings with the SEC. We'll start today's call with brief prepared remarks followed by Q and A. Today's call will contain certain non GAAP financial measures, which we believe are important in evaluating our performance. For more details on these measures, the most comparable GAAP measures and a reconciliation of the 2, please refer to the press release posted on teladoc.com. I now turn the call over to Jason. Thanks, Adam, and thank you to everyone on the call for joining us this afternoon. Teladoc reported another strong quarter after the market closed today. I'm very pleased with our results and the momentum we're seeing across the business. Once again, we met or exceeded our expectations on all our key metrics, recording total revenue of nearly $69,000,000 or growth of over 110 percent adjusted EBITDA loss of $600,000 an improvement from a loss of approximately 9 point $3,000,000 in the same period last year paid membership of 22,600,000 lives or growth of 33% over the prior year and finally, visit volume of approximately 306,000 visits or growth of 51%, representing a quarterly annualized utilization rate of approximately 6.2% or an 84 basis point increase year over year, reflecting the increasing adoption rates by our members resulting from the high impact of our member engagement strategies. Our core Teladoc business performed well in the quarter as we achieved the expected levels of utilization, continued success in penetrating the provider market and strong growth in our behavioral health business. For the remainder of 20 17, we are going to share with you an organic growth rate excluding best doctors. But starting in 2018 and in connection with successful integration efforts, we will be reporting a single corporate wide growth rate. In the Q3, our organic growth rate, excluding Best Doctors, was 45%. Best Doctors, which, as a reminder, we acquired on July 14 this year, performed very well in the Q3 on a standalone basis, and our integration efforts are progressing on or ahead of schedule. We are already having an impact on the business and have recently launched a new member portal and mobile app for best doctors clients. We have integrated best doctors into the Healthiest You product, and we have launched an integrated mobile app with both Teladoc and Best Doctors features for those clients who have purchased both products. This is a substantial step forward in realizing the vision of a comprehensive virtual care platform, and clients are taking notice. I want to take a moment to recognize our employees who have locked arms across the organization to execute on the integration and work to make the vision of the combined company a reality. This commitment is clearly paying dividends. The initial feedback we're receiving from our customers is extremely positive as they instantly recognize the value of the combined offering. We're seeing promising signs of early cross selling and successful joint selling of the solutions. In fact, we have already cross sold or jointly sold Teladoc and Best Doctors products to accounts representing over 1,000,000 members worth several $1,000,000 of annual revenue in just the 1st 90 days since we closed the acquisition. As part of our commitment to realizing our vision of becoming a global virtual care delivery system, spanning the full spectrum of both member and client health care needs and taking the next step in integrating the best doctors and Teladoc teams into one market defining organization, I am very pleased to announce the appointment of Peter McLennan, former CEO of Veth Doctors, to the newly created physician of President of Teladoc Inc. A tenured healthcare executive with deep experience as the CEO, President or COO of multiple healthcare IT companies. Peter has been incredibly effective in growing best doctors to its leading position in the expert second opinion market and has been instrumental in shaping our formational integration efforts to date. Peter will assume responsibility for all commercial operations globally, including sales, account management, product development and strategy for all Teladoc markets and segments. We're looking forward to sharing more with you in regard to best doctors at our Investor Day on November 20, where we will have Peter and many other members of our management team joining us for the day. Before Mark digs into the numbers, I want to provide an update on our selling season so far. First, in the Q3, we saw continued expansion of our relationships with both Aetna and United, rolling out new populations representing 100 of thousands of new members in both of these large health plans. 2nd, we continue to see strong sales activity in our provider segment. We now serve over 200 hospitals, having added 20 in the 3rd quarter alone. Moreover, we have recently closed several new sales, including Orlando Health System and Mercy, Iowa, with many additional large systems in our pipeline. I'm looking forward to hosting our 1st Provider Client Summit later this month, where we anticipate a collaborative discussion about how we can bring new products and services to that segment. And finally, our selling season for new employer and health plan business in 20 18 is in full swing and comparing favorably to prior years. As I've mentioned previously, this selling season was unique with respect to the number of large opportunities that we were pursuing, including both new greenfield accounts as well as opportunities to win business that was previously with a competitor. I'm pleased to say that we have successfully closed large accounts that fall into both of these categories, and I anticipate being able to provide more details on these wins at our Investor Day on November 20. Our business is truly firing on all cylinders today with a strong tailwind working in our favor. Teladoc is extremely well positioned as the only provider in the market who can credibly offer a comprehensive virtual care platform. This is best exemplified by the number of broad strategic C suite discussions at large health plans focused on how Teladoc can help bring a true virtual health system to life for the plan and its members. Given the nature and tenor of these discussions, I'm extremely excited about what 2018 has in store for the company. And with that, I'll turn the call over to Mark to review our financial results from the quarter. Thanks, Jason, and good afternoon, everyone. As Jason mentioned, we are fortunate to see that there are multiple high growth channels within the business that continue to generate strong revenue growth. In addition to our recent large account successes, our behavioral and small and midsized business channels are seeing great demand. We're now 3.5 months into the merger with Best Doctors, and we remain on track with the launch of our integrated service delivery model that will commence rollout during the 1st week of December. Nearly every aspect of the company will experience significant change that will enable us to support our business' long term growth objectives. As we have communicated during the past several months, we believe our increased investment and integration efforts will ultimately position us to accelerate Best Doctor's revenue growth that will approximate our corporate goals. On to the P and L and starting with the top line. Total revenue in the Q3 was $68,700,000 That's an increase of 112% compared to a year ago. As a reminder, we closed the Best Doctors acquisition on July 14, so the results I'm reviewing today include 2.5 months worth of Best Doctors results. On an organic basis, our revenue increased by 45% year over year. Our subscription access fee revenue of $59,800,000 increased 115% compared to a year ago and included approximately $20,000,000 from BEST Doctors. On an organic basis, subscription access fee revenue grew 44% year over year. Breaking out subscription fees between U. S. And international, the U. S. Accounted for $51,600,000 of the total and international generated the remaining $8,200,000 With the inclusion of Best Doctors U. S. And international results, subscription revenues accounted for 87% of total revenue for this quarter. We ended the quarter with 22,600,000 paid members in the United States. I want to mention that as of this quarter, we are refining our definition of members to include just U. S. Paid members that are associated with a PEPM or PMPM or paid U. S. Membership. This change now excludes $1,600,000 formerly included members from Amerigroup. Amerigroup has historically paid Teladoc a flat fee for state by state coverage and this contract, which is not a material amount, is expected to continue into 2018. In 2018, we will also exclude the membership from the Blue Cross Blue Shield Federal Employee Program and Aetna's fully insured population since they will not carry a PMPM. We also exclude Best Doctors International Lives from our reporting. Our international business is distinctly different from our U. S. Business because our international clients purchase our services for their respective consumers to provide a market differentiating service as a complement to their core set of consumer service offerings. We will continue to break out these international results and we believe this approach more appropriately reflects the fundamentals of our business and hopefully affords you better visibility into our global operations and enhances your ability to track our success. Our average per employee per month, or PEPM, was $0.91 compared to $0.61 last quarter and $0.55 a year ago. Excluding the effects from best doctors, our PEPM would have been $0.68 for the Q3. This greater than 20% increase was achieved from a nearly equal contribution from 3 areas: 1st, our behavioral revenue price increases second, we excluded the Amerigroup lives and last, product mix shift in the core Teladoc services, principally in the small business market with the visits included model. Now let me move on to utilization. We calculate utilization as total general medical visits divided by Teladoc paid U. S. Membership for those members that have access to our general medical services. Teladoc completed 306,000 visits in the quarter, a 51% increase over the same period last year. This represents an annualized utilization rate of 6.2%, an 84 basis point increase over last year. As we have often discussed, our Q3 utilization shares the distinction with Q2 of being the lowest period of utilization throughout the year. These visits generate our fee revenue, which accounted for $8,900,000 of revenue in the quarter. General medical visits accounted for $6,800,000 of the revenue, a 49% increase compared to a year ago. Consistent with the product mix I just noted, this quarter's paid visits represented 51% of our total general medical visits. Other specialty visits, which is principally composed of best doctors' expert second opinions provided for health plan clients accounted for the remaining $2,100,000 of visit revenue. Gross margins of 75.6 percent have, as expected, with the impact of best doctors operating at a slightly lower margin as compared to the Teladoc core business, moderated slightly from 77.5 percent last quarter and 78% a year ago as our revenue mix shifted. This is consistent with our long term view as to how our margin profile will change over the next several years. Total operating expenses were $67,000,000 in the quarter. Sequentially, this represents a 44% increase and a year over year increase of 56%. The approximate $21,000,000 increase in costs from Q2 to Q3 of this year was driven primarily by $11,700,000 of Best Doctors operating expenses and $6,400,000 of acquisition and integration related expenses. Adjusted EBITDA continued to improve, coming into a loss of $600,000 compared to a loss of $9,300,000 in the Q3 of 2016. Consistent with our prior comments, we were very close to achieving an adjusted EBITDA breakeven for the 3rd quarter, and we fully expect to achieve positive adjusted EBITDA in this Q4 of 2017. Net loss in the quarter was $31,300,000 compared to a loss of $29,800,000 in the same period last year. Net loss per share was $0.55 compared to a net loss of $0.65 in the same period last year. While our comparable quarter's loss was similar, the decrease in net loss per share was due to the changes to our weighted average common shares outstanding, which increased to 56,500,000 shares in this period compared to 45,900,000 shares in the same period last year, reflecting an increase of approximately 11,000,000 shares, which includes the issuance of 7,900,000 shares from our follow on offering in January, in addition to the approximately 1,900,000 shares issued in July of this year in connection with the Best Doctors acquisition. Turning to our balance sheet. We ended the quarter with over $170,000,000 in cash and short term investments. Our total debt at the end of the quarter was approximately $450,000,000 Now I would like to provide our outlook for the Q4 of this year. We now expect total revenue between $75,000,000 $77,000,000 EBITDA loss between $8,000,000 $9,000,000 positive adjusted EBITDA between $1,000,000 $2,000,000 total paid membership of approximately 22,600,000 to 23,000,000 members total visits between 400,000,450,000 visits and a net loss per share based on 57,100,000 weighted average shares outstanding is expected to range from a loss of $0.41 to a loss of $0.43 We've also updated our outlook for the full year 2017 from our most recent Q2 2017 guidance, and we now expect total revenue between $231,000,000 233,000,000 dollars a change from the previous estimate of total revenue of $230,000,000 to $235,000,000 EBITDA loss between $48,000,000 $49,000,000 a change from the previous estimate of a loss between $46,000,000 to $48,000,000 an adjusted EBITDA loss between $14,000,000 $15,000,000 which is a change from the previous estimate of an adjusted EBITDA loss between $15,000,000 to $17,000,000 total membership of approximately 22,600,000 to 23,000,000 members, reflecting 100,000 member increase to the low end of the previously provided range. Total visits between 1,400,000 and 1,450,000, dollars no change from the prior 2Q guidance and net loss per share based on 55,100,000 weighted average shares outstanding is expected to range from a loss of $1.56 to a loss of $1.58 a change from the previous estimate of a range of loss from $1.52 to $1.55 per share. As our guidance indicates, we are on track to meet the goal we stated on our IPO roadshow over 2 years ago of achieving positive adjusted EBITDA in the Q4 of 2017. I'm incredibly pleased with the tremendous efforts of our entire organization that have helped us to get to where we are today. Finally, I just want to remind everyone that we will be hosting our inaugural Investor Day in New York City on November 20, where we intend to feature several of our colleagues and clients in our presentation of 2018 products, strategy and commercial initiatives for the year. Please visit our website where we have included all of the relevant details. With that, let's open the call to questions. Operator? Your first question comes from Lisa Gill from JPMorgan. Your line is open. Great. Thanks very much and good afternoon. Jason or Mark, can you maybe just walk us through how the new Aetna contract works? So obviously moving away from PMPM, but if I remember correctly, there's some shared savings component to it. So first, if you could help us to understand how that works? And then secondly, Jason, as you've been going through the selling season, are you starting to see where other health plans are interested in a different type of relationship going into 2018? Or do think that this is just really unique to a big player like an Aetna and FEP? Yes. Thanks, Lisa. So let me start with the Aetna contract. First, I just want to remind you that the change to the Aetna contract is only for their fully insured membership, which is about half of the business that we have with them. So, we have about, give or take, 8,500,000 members with Aetna, about 4,000,000 are in the fully insured population and that's the one that we extended the contract and revised the terms. The self insured population stays the same. With respect to the fully insured, we had a few goals from the renewal process. Our first goal was obviously to extend the agreement. 2nd goal was to roll out additional products and services into that population. And we did that as we have now rolled out behavioral health and dermatology for that population. And the third was to make sure that we align ourselves with Aetna's needs and interests and provide us with ample incentive, quite frankly, to expand utilization. And so the new structure does have Aetna paying us a share of savings in addition to the visit fee. So on a total basis, our revenue per visit ends up being almost 4 times what it was previously, which means that we have significantly more upside in the Aetna contract as we drive higher utilization. So that really aligns our interest with Aetna's interest. We're very pleased with how that turned out, and we think that we're aligned and our revenue opportunity significantly increases over time with them. Just to understand that, so when we talk about the shared savings, so is it okay, this population previously had used the emergency room and that cost is $300,000 and Teladoc is $50,000,000 and so we're going to share in some components of $250,000,000 Is that how the shared savings work? I'm just trying to understand kind of the mechanics of what they're looking at when you're thinking about shared savings. Yes. That's exactly we went through an analysis with Aetna with their medical economics group. We agreed on what the total savings per visit is that's generated for Aetna. And then we agreed on how much Aetna would pay us in addition to the per visit fee on a per visit basis. So it's a fixed amount. We don't have to go back and recalculate at the end of the relationship or the end of the year what the measured savings was. We know exactly what we're getting from Aetna on a per visit basis. Okay. Great. And so when I say that the total revenue we're getting per visit is almost 4 times what it was previously, that includes the $40 per visit we're getting as part of the benefit plan plus the per savings payment we're getting or per visit savings payment we're getting from Aetna. Okay. And then as far as this year's selling season, outside of the full risk business here with Aetna as well as the new FEP relationship, Are you seeing any others that, are interested in moving away from this per member per month type of relationship on the paid member side? Yes. So what we're seeing is that our pricing is very much segment specific. So our entire employer book of business is still on a PEPM basis and all new accounts that are coming on in the employer space are on a PEPM plus a per visit fee or a higher PEPM with the visits included model. Our health plans, the vast majority are coming on in our traditional sort of fixed PMPM plus per visit fee. We are starting to do on a more frequent basis, although still as a small minority of our total contracts, situations where we do a lower PMPM to start plus a per visit fee and the PMPM increases as we drive higher utilization. We successfully did that with a large West Coast Blue Cross Blue Shield plan, significantly increased the utilization and as a result increased our PMPM fees. And so we're starting to see some of those and where we feel like we can get good information and good cooperation from the plan on engaging the membership, we're more than happy to do that because we think, again, it aligns our incentives, gives us more upside. And then there are very few, but a few cases where we have large opportunities that lend themselves to more creative arrangements like the FEP population or the Aetna population. And as long as those meet our hurdle rates and give us good insight and predictability into revenue, we're happy to do that. And I think we'll talk more about that as we give some insight into what the selling season looks like in later this month on November 20 at our Investor Day. I'm looking forward to the Investor Day. And if I could just ask one other question and that would be, Jason, I like the way you're talking about this virtual care platform and what you've been able to do via acquisitions, whether as best doctors or Healthiest You, we think about dermatology, behavioral health. Are there any other verticals that you think you need to add via acquisition? Or do you think, hey, we have the pieces that we need today and will primarily grow organically? Right now, we're very focused on successful integration of Best Doctors and rolling out an integrated platform that ranges from sort of episodic urgent care all the way up through more catastrophic or complex conditions and does that with a single front end that's intuitive for the consumer. Once we execute on that and bring that to market, number 1, that will be completely differentiated in the market relative to anything else that's out there. And number 2, at that point, we'll start to look at where it makes sense for us to add additional clinical capabilities and programs either through in house development, through partnership or potentially through further acquisitions. But we would do that out in the future once we bring this to market and execute on the successful integration of the companies. Your next question comes from Sean Wieland from Piper Jaffray. Hi, thanks and congrats on all the progress. My question is on Best Doctors. You said that you sold to some accounts worth more than 1,000,000 members. Can you maybe unpack that a little bit on how that conversation is going? And then specifically, when you do cross sell best doctors into an existing customer, how does the math what's the math on the uplift on the revenue of that customer? Yes. Thanks, Sean. So I'll go through adding a little more color on the cases that we've sold either cross sell or joint sell and then Mark can go through the math on sort of a unit basis. The nice thing is we're seeing sort of all three of the things that we would have hoped for. 1 is selling best doctors into existing Teladoc clients, and we've done that for the small employer market alongside or integrated into Healthiest You. We've done it in the large employer market, both where we're selling second opinion services for the first time that the client's buying them as well as displacing competitors who were in Teladoc accounts, but the account had a different second opinion service. And then on the end, we are actively in discussions with a number of our health plans to put best doctors through their ASO channel into their large employer self insured clients. On the other side, we're being successful in selling Teladoc into best doctors clients. And then the third one is we are we have some significant successes in selling a joint product to clients who didn't have either Teladoc or Best Doctors, but were running processes either in 1 or both of the areas and have signed up to buy both products side by side. And as I said, we've now brought to market an integrated app. So there's a common front end for the consumer. And Sean, I would just add that in based on the respective channel, we're seeing pricing from a couple of dollars up to many dollars for those clients that are sold through the small and medium sized business channel. So we've been active in quoting accounts with 50,000 and greater employees as well as introducing the service to health plans with 100 of thousands of members. And we've been actively selling a day to day basis into small and medium sized businesses that are closer to a couple of 100 employees with the combined service on either Healthiest You and Best Doctor's core services or the Teladoc core service added to the best doctor services? So what I was trying to get at is if I'm a Teladoc, let's say I'm a Teladoc employer customer and I add best doctors to my existing terms of my contracts, Can you give me a sense for what that lift is to you? Sure. You can think of a traditional client with approximately 5,000 lives, paying Teladoc somewhere in the range of, let's say, dollars 2 per employee per month and they would likely be at the $3.50 range with the uplift from the best doctors additional services. Great. That's helpful. And, how about a bigger picture question, this opioid problem that we have, telehealth is getting a lot of airtime in that. I was wondering if you guys have a strategy around that or any commentary that you have on that opportunity? Yes. I think from a big picture perspective, I'm certainly very pleased to see telehealth getting more recognition and support in Washington. We see that happening both in Congress as well as at CMS. So I think that that bodes very well for our future and for telehealth's role in the overall health care system. With respect to the opioid crisis, obviously, this is a very significant issue and it's a complex one. We are looking at possibilities there. We don't currently have a program. There are some complexities relative to the treatment of those of that condition and doing that in a remote environment. So no big announcement for me here on a program focused on that. But as this continues to get significant attention, we make sure that we're following and if we see an opportunity to roll something out in the market, then we'll certainly take advantage of that. Okay. Thank you very much. Thanks, John. Your next question comes from Jamie Stockton from Wells Fargo. Your line is open. Thanks. Hey, good evening, guys. I guess maybe, Mark, the best doctors revenue during the quarter, I thought you guess that it was going to be like $22,000,000 and it sounds like it came in closer to 20 percent. Is that right? Is there kind of any color on that? Any thoughts on the contribution in Q4 and how all that plays into what your new revenue guidance is? Yes, Jamie, we finished up at $21,800,000 So the $22,000,000 is appropriate for the expectation for what was delivered in the Q3. Recall that the quarter was short by 2 weeks as we closed on that transaction in mid July. So they're tracking and trending above what we had expected when we presented this transaction to our Board and the underlying valuation that we used was obviously dependent upon their projections. We're extremely pleased with both their top line and especially their bottom line. So that's why we've got some good Q4 expectations and a run rate coming into next year with even better contribution on the bottom line. All right. And then the core business, it seems like we saw a decent acceleration sequentially in the organic with the Better Health business? Or is there something else going on? Yes. You're right. We did have great organic growth, 45% quarter over quarter. There was a I'd suggest an equal contribution, 2 areas, The behavioral health entity is now contributing in excess of $25,000,000 annually. You recall that was about $12,000,000 last year and they are likely going to again grow in excess of 50%, likely we'll achieve numbers potentially at the 75% growth rate going into 2018. Additionally, we did have some obviously good volume coming in at the beginning of the year. That was at slightly higher PPM rates. We had that sort of nickel. If you think of our if you think of the PEPM growth over the quarters, We spoke about what it was with the impact of eliminating that Amerigroup lives. But if you look at it on a same store basis, Q3 of 'sixteen was $0.49 All quarters of 'seventeen exceeded $0.50 and in Q3 of this year, we were at $0.53 So that organic growth, that 45% organic growth really came from those two components. All right. That's great. Thanks. Sure. Your next question comes from Sandy Draper from SunTrust. Your line is open. Thanks very much for taking the question and congratulations. First, just a quick housekeeping item. On the international nub figures you gave, Mark, all of that is from best doctors. Is that correct? Is there any core Teladoc that's international? I want to make sure I've got that right. No, you're correct, Sandy. That is all Best Doctor's revenue from clients such as Great West, Sun Life, MLC, RBC, these are all extremely large insurance and financial services companies. Okay, great. And then, following up on the Aetna contract, to make sure I understand that with their fully insured, are you guys now automatically in all of that or is this the and is Aetna bidding that out to everybody or people, someone is on the fully insured side with Aetna, can they elect not to take down the Teladoc services? We roll out segment by segment or market by market in the fully insured business. So they're not bidding it out. We are their telehealth provider of choice, but you have market leaders for each one of their markets and segments who make the decision about when to roll it out. So as I mentioned in the prepared remarks, we did roll out to a new population, a student population over the course of the quarter. That was an expansion of our service or of the population that we're being provided to. We're looking at several other additional markets to roll out to that will again then have access to the Teladoc service as part of their overall benefits package. Okay, great. That's helpful. And just final question, as we continue to see more momentum building for you guys in the whole telehealth market, are you finding any challenges in terms of finding doctors? And I can't remember if you've given us a recent number of doctors that are certified on the Teladoc network and just trying to think about what type of growth that needs to do in order to keep supporting the top line growth that you guys are doing? Thanks. Yes, Sandy. It's a good question. We haven't given 1 in probably a couple of quarters. It's probably a metric that we can look at providing on November 20. We're not, however, having a challenge with bringing doctors on. In fact, I was on the phone today with the person who leads our recruiting efforts and we just credentialed a couple of 100 physicians into the network as we are now ramping into the busier season with cold and flu season. So, we don't see that as a significant constraining factor for us. We continue to have strong capacity and strong response times as volume increases as we head into cold and flu season. Great. Thanks very much. Yes, absolutely. Your next question comes from Richard Close from Canaccord Genuity. Your line is open. Great. Congratulations on the execution. Guys, I was wondering if you could give us a little bit of, I guess, comfort with respect to the visit guidance for the year? I know you maintained that. Obviously, there's been rampant pressure across the industry with respect to volumes. And I understand, obviously, telemedicine, there's a shift towards telemedicine. But what gives you the confidence in the 400,000 to 450,000, I guess target for the Q4? Hey, Richard, it's Mark. So to date, we've completed over 1,100,000 visits. And had we seen a much earlier increase in flu type visits, we likely would have reassessed our earlier communicated figures and the targets that are out there today to have lifted that. But we're comfortable with and we have visibility into where we are today to the extent that those numbers should come to fruition. We saw one of our highest days of the year this past Monday and we're comfortable based on providing 10 years of in excess of 10 years of these virtual visits and tracking that based where our membership is today, we should achieve that a number within that range. Richard, the other thing I guess I'd add to that is that we are now in the midst of our fall communications campaign, which is a multichannel communications effort in order to drive awareness and utilization. And the early results are very strong. And so we're comfortable that the modeling we've done around that and the yield we get from those efforts will drive the results that we've projected. Okay. You had mentioned United earlier in some of the commentary with respect to Aetna and continuing to add individuals there. Can you talk a little bit about where you started with United, where you opportunities going forward? Sure. We're very pleased with that relationship and how it continues to evolve. We did roll out to some new populations both in the government programs for them as well as in the commercial sector. We are also in discussions with them about some additional populations as we look into 2018 and about how we can bring some additional products and services to bear for them. So we feel very good about it. We're well over 1,000,000 members now from the United sort of family of products and markets. And we have high expectations for 2018. Okay. And final question is housekeeping, Mark. In terms of talking about the membership base, I just wanted to be clear, you may I guess raised the bottom end a little bit on that. But with all the puts and takes that you mentioned, Amerigroup coming out, can you just go over that again so everyone's clear on that? Sure. Rich, we excluded about 1,600,000 members that are in a number of states that Amerigroup has had under contract with us for many, many years, probably around 10 years. That contract continues, but they pay us a flat fee per state. Their membership hasn't changed that much and their utilization is extremely low. We have not had opportunities with Amerigroup to initiate any internal or any other programs with them to generate additional utilization. So we feel that by including those numbers, it's somewhat diluted and doesn't give a clear picture as to the increasing utilization over the rest of the population. And again, that contract stays in force. While it's an insignificant financial contract, we'll continue to service those members in 2018 and beyond. So you're saying you pulled those members out of your new guidance on members or That's correct. Okay. So you would have raised your membership based on the previous way you looked at it? Sure. If we had not taken on both U. S. Paid membership from Best Doctors and excluded the Amerigroup lives, we'd still have a net increase in contribution. But between quarters 23 and sequentially, that membership was essentially flat as to be expected since we barely add lives other than health plan lives if they land in the middle of the year in that 6 month period. Okay. Thanks for the clarity. Sure. Your next question comes from Ryan Daniels from William Blair. Your line is open. Yes. Thanks for Jason, a follow-up for you on the new Aetna agreement. I'm curious with the incentives you have to markedly increase the long term value of the relationship there. If you've also gotten more commitment from them to enable you to market it more effectively, things like email addresses or ability to contact the membership base more actively going forward? Yes. It's a great question and the answer is yes. As part of our agreeing to the new structure, we have gotten access to significantly more data that enables us to more effectively target that population and get greater yield out of our communications efforts. So that was a part of the agreement and puts us in a place where we feel confident about the ability to drive higher utilization and realize the upside of that contract. Okay. That's helpful. And then based on the current contract terms and utilization, should we think of this about coming out of the box in the first quarter is maybe dilutive to revenue, but for the full year neutral or accretive as you drive that utilization? Or just how should we think about the step function there and run rate revenue for Aetna 2017 versus 2018? And then how that might see a cadence change throughout the year? Yes. Ryan, it's Mark. We would expect the revenues to be either neutral or slightly stronger than what we saw in 2017. It might be lumpy as a result of the fact that's going to follow our traditionally heavier seasons quarter 1 and quarter 4. And quite frankly, we'll see and we expect to see an increase quarter over quarter from 2018 to 2017 in Q1 and we'll likely see that drop in Q2 and Q3 and it will be hopefully a strong quarter end in Q4 of 2018 and run rate revenue should be significantly greater. Okay. That's helpful color. And then last question, I'll hop off. Just on the 2018 selling season, you mentioned that it's trending favorably versus the year ago. I'm curious how far along in the season are you with only 2 months left? Or maybe as differently, how high is your visibility into 2018 membership? Not asking for guidance, but just level of visibility today and how does that contrast to past years? Thanks. Yes, Ryan. We have we were looking at that just over the last week or so, and we figure we're at about 90% visibility into our 2018 revenue, which is slightly higher than we were at this time last year. We feel pretty good about where the selling season is. We're still seeing a lot of business come in. And in fact, that reflects the strength of our small and midsized employer market, efforts mostly focused on the Healthiest You product, but also through some of our reseller channels. So we feel very, very good about that. And again, at about 90% visibility, we're very pleased with how the selling season is shaping up. Okay, great. Thanks and congrats on all the momentum. Thanks, Ryan. Your next question comes from Mohan Naidu from Oppenheimer. Your line is open. Thanks for taking my questions. Jason, one more on Aetnaive contract. Now that you have access to the members and can run direct campaigns, is there anything unique in these members that can prohibit you from getting to the current book rate of 6 percent utilization? And also, are there any internal targets that you can share about how you expect that utilization to grow? So I won't share what our own internal targets are. But I will say that with the additional data, we do feel good about our ability to increase the utilization rate. I mentioned earlier that we have a West Coast blue plan, who we put not exactly the same structure in place, but a similar incentive for us to drive higher utilization. And we've been able to increase utilization at 17 over 16 by about 50%. So we feel good about our ability to replicate that and maybe even do a little better. Having said that, I wouldn't set expectations around 6%. It's always harder to reach a fully insured population and get them motivated to engage than it is an employer population because people are less tuned in to their health plans than they are to their employers. And so I want to I don't want to set your expectations that we're going to get to 6% on that population, but I do feel very good about us increasing the utilization substantially. Okay, great. A couple of numbers questions, Mark. On Q4, I think Jamie asked you this, but I just want to get some clarity. You're still expecting $25,000,000 to $26,000,000 for Q4 from Best Doctors? Yes. We didn't break out the exact number, but Moe, we did approximately $22,000,000 for the reduced quarter, the Q3. So you should expect to see the jump for the additional 2 weeks and clearly a little bit greater impact from more volume. Okay. And there is no seasonality in Best Doctors, right? Yes. There is little seasonality compared to traditional Teladoc. That's correct. There's obviously the seasonality that comes about as a result of new contracts commencing in Q1. But beyond that, there's nothing aligned to what we experience when we see heavier cold and flu seasons. Okay, got it. One last one, going back to the membership and how that's going to change into ATM, can you provide us a net number if you exclude right now all the non paying members out of the 22,600,000 members? Well, everybody today is paying in that fully insured that will transition to the different construct of the medical cost savings or share savings in 2018. And then obviously, we'll be adding those millions of members that will not go into our calculation for the FEP membership. That's the only 2 entities that I could identify now. Okay, got it. Thank you very much for taking my questions. Sure. Your next question comes from Matt Hewitt from Craig Hallum Capital. Your line is open. Good afternoon, gentlemen. Just a couple from me. First up, with the FEP relationship, and I apologize if I missed this, but given the change in how that contract is structured, how do you intend to drive utilization with that group? And who is going to be footing the bill for the education of the employees? So, Matt, that's a new contract. So it's not really a change. It's a de novo relationship that will start in January of 2018. The structure of that relationship is such that there the FEP organization, through the Blue Cross Blue Shield Association is responsible for communications unless they employ us and pay us an incremental fee to perform those services for them. So it's a contract that has a significantly lower cost basis to us because we're not footing the bill for communications or welcome kits or things like that. And then the opportunity there, of course, is to work with the FEP organization as well as the 38 member plans who serve those populations in order to help them promote the service. We do that on by the base contract on more of a consultative basis and they have the option of purchasing engagement strategies and services from us. The other benefit of that contract, just to say it, is that it gives us a foothold in all of those 38 member plans. And we've already won business as a result of the FEP selection of Teladoc. And when I say we won business, it's with BluePlan, so we're not previously working with us. But piggybacked on the FEP RFP process. And those contracts have been closed at our more traditional PMPM plus visit fee structure. That's very, very helpful. Thank you. One more question. You mentioned early on that you guys are becoming a little bit more creative in some of the bidding processes. And I'm wondering if that's being driven by the customer or by your desire to maybe expand markets? Or is it due to competitive certainly not a reaction to the competitive environment. And to be honest, we've, I think, done a very good job of differentiating ourselves in the market as we're now really selling something very different from anybody else. It is more about us getting more sophisticated in understanding our business, understanding the levers of growth and how we can align ourselves with our clients in a way that maybe takes a little bit of risk off of the client, gives us more upside. And in response to what we've heard from our clients in terms of their interests and goals, be able to deliver something that meets those goals. So yes, I think 2 or 3 years ago, we wouldn't have felt comfortable because we didn't have as sophisticated analyses into the data and the performance of our markets and our ability to drive utilization using digital channels that are much more efficient and much more targeted and effective as we do today. And so as our business gets more sophisticated and our ability to predict that utilization gets more align everybody's interest and give us better upside. Understood. Thank you. Absolutely. Your next question comes from Matthew Gillmor from Robert Baird. Your line is open. Hey, thanks for the question. Just one more for me. On the provider segment, you'd mentioned that growth there has been very strong. So just wanted to get an update in terms of what you're seeing from a product demand standpoint and how you see that market evolving. Are health systems more focused on outreach to patients in their markets or more focused on leveraging specialists, both in and outside their networks to provide better coverage? Yes. It's a really diverse set of use cases and priorities for the health systems. In our employer markets and our health plan markets, they're much more consistent and it's a much narrower set. With hospital systems, they are very diverse. Some of them are looking for referrals and driving increased patient populations and patient acquisition strategies. Some of them are looking at financial risk management as they take risk for the populations and therefore more efficient delivery of care and less leakage outside of their systems. Some of them are very focused on readmission avoidance and using telehealth to do follow-up care. We do have some of them using the platform for specialty consultations within their systems. And then of course, many of them are looking at their own employee population as an expensive health care cost and therefore they look at us more like an employer does. So I can't give you a single use case because it's a pretty diverse set. And I think our sales organization in that segment is very, very good at understanding the needs and priorities of the client and helping to tailor a solution to their needs. Got it. That's helpful. Thanks very much. Yes, absolutely. Your next question comes from Stephen Wardle from Chardan. Your line is open. Hi guys. Thanks for taking my question. Sure. So how do you drive engagement with health plan members as compared to the way that you drive it with employers? And relatedly, do health plans give you access to full access to members the way that a typical employer would? It's different from health plan to health plan. They're not uniform. Our efforts are frequently similar for the health plans versus the employers, although many times we're doing more in concert with the employer than we can do with the health plan. So obviously things like on-site, being on-site, helping to facilitate, employee to employee peer, word-of-mouth and referrals are things that are much more easily done in an employer environment than they are in a health plan environment. But we are able to do very effective digital targeting among our health plan members. And of course, we can be incorporated into the health plan's communications to their membership, whether that's in their overall benefits information, through their digital channels, on EOBs or other things. And we use all of those channels among our various health plan customers. And is it still the case that you generally seek to do contracts around a managed care organization's self insured book of business and not its fully insured? No. We target both of those populations. So I talked about Aetna earlier. That's about 50% self insured membership, 50% fully insured membership. And we work with plans across the country just like that. Great. Thank you. Thanks, Steve. Your next question comes from Rohan Abhral from KeyBanc Capital Markets. Your line is open. Hey, Jason. Just a couple of quick ones for me. I believe in 2Q, you had given some breakdown with respect to the kind of mobile appwebsite versus landline breakdown. I think you had a 55%, 45%, respectively. Any update to those numbers, gradual or not? Pretty similar results in the Q3 to the 2nd quarter, maybe a point additional swing from offline to online to digital channels, but pretty similar results. Okay. And then I believe you had also commented on existing BetterHelp subscribers. I think it was roughly 15,000 as of 2Q. Any update to that number? No, it's about the same today. Okay. And then I guess finally more thematically, given the potential CVS Aetna tie up, any kind of vision as to what that could foretell for Teladoc strategy wise, perhaps more monitoring services within a MinuteClinic or whatever it may look like? We have very good relationships with both CVS and obviously with Aetna and we are actively talking to CVS about expanding that relationship. And so I feel very good about our position there and think that if that were to come to pass, it would only be positive for us. Awesome. Appreciate it. Your next question comes from Steve Halper from Cantor Fitzgerald. I actually have two questions. So when you exclude the membership relating to the Federal Employees Plan and the Aetna fully insured book as well as Amerigroup, is there going to be another revenue item to reflect the revenue that you're earning from those contracts? If not, where is it going to go? Yes. The revenue from those contracts, Steve, will go into visit revenue. Even on the shared savings arrangements? Yes. Principally on the shared savings because those are based only on completed visits. Okay. And then the other question is when you look at the full year guidance, you obviously tightened the range with the high end coming down a bit. What didn't materialize that might have suggested you would have gotten to that higher end? Or is it or are you just bringing that in just because it's the Q4 and you have really good visibility at this point with 2 months to go? Well, I've actually only got 1 month to go because I've billed November already, Steve. And the reality is, we set these numbers at the beginning of the year and bringing it down by $2,000,000 to me, again, with enhanced visibility, that's where we're feeling comfortable. It's an insignificant change in our mind since we've still achieved again nearly 50% organic growth for the year. Yes, fair enough. Great. Thank you. Okay. Thanks, Steve. Your next question comes from Samantha Warman from Cowen. Your line is open. Yes. Actually, it's Charles here for Samantha. Hey, guys. Thanks for squeezing me in. Just first a quick clarification around the question on the opioids. If I'm not mistaken, you can't get prescribed Class 2 II drugs through telehealth. Is that correct still? Yes. We don't prescribe or we don't permit our physicians to prescribe any scheduled drugs. So when I said that there are some complexities relative to the treatment of opioid oriented conditions or addiction specific to telehealth, that's what I was referring to. Okay. That's helpful. A second, just a quick question on the prior question on CVS. Can you remind us what the current relationship you have with CVS? I recall you guys putting out some release or CVS maybe did, maybe looking at some pilots. Just trying to get an update there. Like, is there an official relationship that you guys have in terms of contractually? Or is it we still kind of been in sort of a continuous pilot phase? Just curious. Well, we have a contractual relationship that Well, we have a contractual relationship that started with the pilot. We also served their employees with our traditional Teladoc service for their employee base. And we're, I would say, actively exploring expansion of our relationship. Okay. That's helpful. And then lastly around utilization and as we think on to the future. Jason, if I remember, I think in the past you guys have talked about sort of your typical kind of commercial clients, utilization 1st year sort of low mid single digits, it kind of goes up year 2 and then it can take a kind of a big jump in year 3. And if I look back if I look at the P and L or sort of the membership growth over the last several years, it looks like we've had some big pickups in the last couple of years. Should we start to think about modeling that in where we're going to get to kind of the steeper part of a utilization ramp as we get your older customers kind of maturing into that year 3? And is that should we think about 2018? I know it was a little early here, but is that a 2018 more of event? Or should we think about that as more of a 2019 event? Thanks. Yes. So there's no question that we do see the benefit of that. But as you say, it's dampened by the membership increases that we see across the book of business and so many millions of lives that we bring on in year 1 and therefore have lower utilization levels. As the book matures, you'll see that more. I think you'll start to see a little bit of that in 2018 and a lot more of it in 2019. If you look at how many members we added this year, it's certainly that's a significant dampening effect on that inflection. No, that's fair. And I guess last question for me. On the provider business, can you give us sort of your thoughts on this? And particularly, obviously, a lot of positive news coming out of Washington. It looks like Medicare is beginning to move here. You have expected decisions in MedPAC coming. How much of this how much do you think how much would you actually handicap that the lack of Medicare reimbursement has limited growth in the provider segment versus, let's say, the employer segment? And would you expect that to change? I would be reluctant to give you a percentage or try to approximate how much that has dampened the growth from the provider segment. I will say that I think, as we look at the chronic act that seems to be gaining traction through Congress and the likely impact of that, that's probably a 2019 impact because the language that's in there enables health plans or MA plans to put in telehealth as part of their bids in the 2018 bidding season for 2019 and 2019 for 2020 really. So So it's out there in the future. I do think that it will be positive. But I guess the other thing I'd say is we try really hard not to put any of that stuff that's more binary and out of our control into our forecasts and projections. Okay. Thanks a lot. Thanks, guys. Absolutely. Thanks. I appreciate it, Charles. There are no further questions. Thank you for joining Teladoc's 3rd quarter earnings conference call and webcast. You may now disconnect.